Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 4 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 5Hematologic Neoplasms 2Cardiotoxicity 2Sarcoma 1Prostatic Neoplasms 1Lymphoma 1Heart Failure 1Cardiovascular Abnormalities 1Breast Neoplasms, Male 1

Interventions

Doxorubicin 8Cyclophosphamide 4Docetaxel 3Atorvastatin 3dapagliflozin 2Trastuzumab 2Chemotherapy, Adjuvant 2Carvedilol 2nicotinamide-beta-riboside 1empagliflozin 1Tablets 1Reverse Transcriptase Polymerase Chain Reaction 1Radiotherapy 1Paclitaxel 1Neoadjuvant Therapy 1Methotrexate 1Metformin 1Mass Spectrometry 1Lisinopril 1Leucovorin 1Lapatinib 1Hydroxymethylglutaryl-CoA Reductase Inhibitors 1Gene Expression Profiling 1Fluorophotometry 1Filgrastim 1Fenofibrate 1Epirubicin 1Environmental Biomarkers 1Echocardiography 1Dexrazoxane 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Cardiotoxicity × Carvedilol × Clear all
NCT06844669 2026-05-13

HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy

Washington University School of Medicine

Phase 2 Terminated
7 enrolled
Breast

Breast Neoplasms, Heart Failure, Cardiotoxicity

NCT01009918 2021-03-30

Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab

University of South Florida

Phase 2 Completed
468 enrolled 16 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡